Comparison of the clinical history of symptomatic isolated muscular calf vein thrombosis versus deep calf vein thrombosis  by Galanaud, Jean-Philippe et al.
Comparison of the clinical history of symptomatic
isolated muscular calf vein thrombosis versus deep
calf vein thrombosis
Jean-Philippe Galanaud, MD,a,b Marie-Antoinette Sevestre, MD,c,d Céline Genty, MS,c,e
Jean-Pierre Laroche, MD,f Violaine Zizka, MD,g Isabelle Quéré, MD, PhD,a,b
Jean-Luc Bosson, MD, PhD,c,e and the OPTIMEV SFMV investigators, Montpellier, Grenoble, Amiens,
Avignon, France; and Fort de France, Martinique
Background: Half of all lower limb deep vein thromboses (DVT) are distal DVT that are equally distributed between
muscular calf vein thromboses (MCVT) and deep calf vein thromboses (DCVT). Despite their high prevalence, MCVT
and DCVT have never been compared so far, which prevents possible modulation of distal DVT management according
to the kind of distal DVT (MCVT or DCVT).
Methods: Using data from the French, multicenter, prospective observational OPTimisation de l’Interrogatoire dans
l’évaluation du risque throMbo-Embolique Veineux (OPTIMEV) study, we compared the clinical presentation and risk
factors of 268 symptomatic isolated DCVT and 457 symptomatic isolated MCVT and the 3-month outcomes of the 222
DCVT and 390 MCVT that were followed-up.
Results: During the entire follow-up, 86.5% of DCVT patients and 76.7% of MCVT patients were treated with
anticoagulant drugs (P  .003). MCVT was significantly more associated with localized pain than DCVT (30.4% vs
22.4%, P  .02) and less associated with swelling (47.9% vs 62.7%, P < .001). MCVT and DCVT patients exhibited the
same risk factors profile, except that recent surgery was slightly more associated with DCVT (odds ratio, 1.70%;
confidence interval, 1.06-2.75), and had equivalent comorbidities as evaluated by the Charlson index. At 3 months, no
statistically significant difference was noted between MCVT and DCVT in death (3.8% vs 4.1%), venous thromboembo-
lism recurrence (1.5% vs 1.4%), and major bleeding (0% vs 0.5%).
Conclusion: Isolated symptomatic MCVT and DCVT exhibit different clinical symptoms at presentation but affect the same
patient population. Under anticoagulant treatment and in the short-term, isolated distal DVT constitutes a homogeneous
entity. Therapeutic trials are needed to determine a consensual mode of care of MCVT and DCVT. (J Vasc Surg 2010;52:932-8.)From the Vascular Medicine Unit, Department of Internal Medicine, Mont-
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932Distal deep veins of the lower limb are made up of
muscular (gastrocnemius and soleal) and deep calf—
paired—(anterior and posterior tibial and peroneal) veins.1
In venographic series, the proportion of distal DVT was of
20% of all DVT, notably because the exploration of muscle
calf veins requires a special examination protocol and they
were not systematically searched.2 With the possible mod-
ification of referral patterns, the use of color flow duplex
ultrasound (US) imaging that has a sensitivity, a specificity,
and an overall diagnostic accuracy 87% than contrast
venography at the level of the calf, and a shorter time lag
between the onset of symptoms and the realization of the
diagnostic test, distal DVT now represents up to half of all
lower limb DVT, roughly equally distributed between mus-
cular calf DVT (MCVT) and deep calf DVT (DCVT).2-7
So far, international guidelines recommend treating
isolated distal DVT for 3 months with full therapeutic doses
of anticoagulants, without modulating the treatment ac-
cording to the muscular or deep calf vein location of the
thrombosis.8,9 This is mainly explained by the fact that distal
DVT management is itself still debated and by the absence of
comparative data between MCVT and DCVT.2,4
However, if the natural rate of extension of distal DVT
(MCVT and DCVT) to proximal deep veins was generally esti-
mated to be about 10%, MCVT natural history—rate of exten-
sion to proximal deep veins and postthrombotic syndrome po-
tentials—probably differs from that of DCVT.4,10-14 This
difference may be the consequence of the anatomy of mus-
ulmo
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lower volume of thrombus and, for soleal veins, their higher
distance from the proximal veins than deep calf veins.
Another explanation may be a difference in patient profile
as it has been previously described between distal and
proximal DVT, for example.15,16
Thus, distal DVT might be a heterogeneous entity
affecting two different populations according to the kind of
DVT (MCVT and DCVT). With this perspective, we ana-
lyzed the data of the prospective, multicenter, observa-
tional OPTimisation de l’Interrogatoire dans l’évaluation
du risque throMbo-Embolique Veineux (OPTIMEV)
study of inpatients and outpatients with objectively con-
firmed symptomatic venous thromboembolism (VTE). In
this substudy, we focus on symptomatic isolated DVT, that
is, without proximal extension or symptomatic pulmonary
embolism (PE) at presentation and treated with conven-
tional anticoagulant therapy. The objectives of this work
were to compare the clinical characteristics at presentation,
the risk factors profile, and the 3-month clinical history of
symptomatic MCVT and DCVT to evidence possible dif-
ferent populations. These results may provide a basis to
investigate whether distal DVT management should be
Fig. Patient enrollment and follow-up. DCVT, Deep
follow-up; MCVT, muscular calf vein thrombosis; PE, pmodulated according to the kind of DVT.MATERIAL AND METHODS
The study protocol has been extensively described else-
where.15,17,18 It is available at ClinicalTrials.gov (registra-
tion number: NCT00670540). The study was approved by
the Ethics Committee (Comité Consultatif sur le Traite-
ment de l’Information en matière de Recherche dans le
domaine de la Santé) and the Comission Nationale de
l’Informatique et des Libertés (CNIL). All participating
patients received written information explaining the study
objectives and could decline telephone follow-up and con-
sult their data.
Patients. Briefly, between November 2004 and Janu-
ary 2006, the study enrolled 8256 patients aged18 years,
referred to the vascular medicine physicians of the 41
hospitals and 292 private practices participating in the
study for clinically suspected VTE (DVT or PE; Fig).
All eligible patients underwent a comprehensive real-
time B-mode and color Doppler US examination of both
legs by a vascular medicine physician. The following veins
were scanned transversally over their entire length: inferior
vena cava, iliac veins, femoral veins, popliteal veins, anterior
and posterior tibial veins, fibular veins, medial and lateral
vein thrombosis; DVT, deep vein thrombosis; F-U,
nary embolism.calfgastrocnemius veins, and soleal veins.19 The diagnosis of
JOURNAL OF VASCULAR SURGERY
October 2010934 Galanaud et alDVT was confirmed if there was incompressibility of the
vein. Only clots 5-mm in diameter on US were consid-
ered as distal DVT.3,20 The diagnosis of PE was confirmed
according to the Prospective Investigation of Pulmonary
Embolism Diagnosis (PIOPED) criteria and after valida-
tion by an independent expert committee.21,22 This study
only took into account the 725 patients exhibiting a symp-
tomatic isolated MCVT or a symptomatic isolated DCVT
of lower limbs.
Study protocol. At inclusion, all demographic charac-
teristics, clinical data, and diagnostic test results were pro-
spectively collected by the vascular medicine physician. At 3
months, patients were asked by phone by clinical research
associates to disclose all health-related events since inclu-
sion. The general practitioner or the vascular medicine
physician was contacted whenever a possible event was
disclosed, and medical records were reviewed in case of
hospitalization or a new visit to the vascular physician
during this follow-up period. Routine follow-up US exam-
inations were not performed. For practical reasons, patients
enrolled in overseas territories, living outside of France,
homeless, or for whom case report form completion was
delayed were not eligible for follow-up.
Distal DVT. MCVT were classified in soleal or gas-
trocnemius DVT. DCVT were classified in tibial posterior
(or anterior), peroneal, and calf trifurcation DVT. Because
the reported rate of tibial anterior DVT is very low (1% of
all distal DVT), tibial anterior DVTs were classified among
tibial posterior DVTs.3,5 To have the most homogeneous
groups of distal DVTs as possible, the study excluded 208
combined MCVT and DCVT (22.3% of all isolated distal
DVT).
Clinical symptoms at presentation. The clinical
symptoms of screened DVT were swelling, dull or localized
pain, and warmth of the lower limb. The Wells clinical
pretest probability score was calculated for each patient.23
Risk factors. The influence of the following potential
risk factors for DVT was analyzed: age, sex, inpatient or
outpatient status, and anticoagulant treatment at inclusion.
Chronic risk factors for DVT studied were a personal or a
family history of VTE of any kind, active cancer, varicose
veins (CEAP 2), estrogen therapy within the last 2
months, and obesity (body mass index30 kg/m2). Tran-
sient risk factors analyzed were bed confinement, recent
plaster immobilization of the lower extremities, recent
travel (ie, travel3 hours in the last month), surgery within
the previous 45 days, congestive heart failure (New York
Heart Association class III or IV) or respiratory insuffi-
ciency (acute respiratory failure or exacerbation of chronic
obstructive pulmonary disease), infectious disease, and
pregnancy or recent childbirth (ie, early postpartum, 6
weeks). For each kind of DVT, comorbidities of the pa-
tients were estimated according to their Charlson index
score.24
Study outcomes. The study outcomes were recurrent
VTE (PE or DVT), major bleeding, and overall mortality at
3 months. If a recurrent DVT was suspected, a complete
US examination of the lower limb was performed. Thediagnosis was confirmed in case of noncompressibility of a
previously normal venous segment or of an enlargement of
thrombus thickness2 mm. Major bleeding episodes were
fatal bleeding and overt bleeding within a critical organ (eg,
intracranial, retroperitoneal, intraocular, pericardial, in-
traspinal, or in the adrenal glands) or associated with a fall
in hemoglobin level 2 g/dL, or leading to a transfusion
2 units of packed red blood cells or whole blood. An
independent expert committee adjudicated all the clinical
outcomes.
Statistical analysis. Categoric variables are expressed
as frequency and percentage; continuous variables are ex-
pressed as median and range. In univariate analyses, poten-
tial risk factors for VTE and 3-month outcomes were
estimated using a 2 test for categoric variables or a Fisher
test when the theoretic size of a group was 5, and the t
test was used for continuous variables. A multivariate logis-
tic regression was performed to estimate the adjusted odds
ratios (OR) and corresponding 95% confidence interval
(CI) associated with each risk factor for MCVT and DCVT.
The independent covariates entered into the logistic regres-
sion models included age, sex, risk factors for VTE, inpa-
tient vs outpatient status, and the use of anticoagulant
therapies at the time of enrollment.
Cox models were performed to evaluate the influence
of MCVT and DCVT on the occurrence of each 3-month
clinical outcome. The independent covariates entered into
the Cox models included age, sex, inpatient vs outpatient
status, and anticoagulant therapy duration. In our multi-
variate analyses, we systematically assessed all first-order
interactions involving the inpatient vs outpatient status. To
account for patient clustering within enrolling physician
practices, random intercept logistic regression models with
the two levels defined by patient and physician were used.
Two-sided values of P  0.05 were considered statistically
significant. Statistical analyses were performed using Stata
10.0 software (Stata Corp, College Station, Texas).
RESULTS
Population characteristics. Of 725 patients with an
isolated distal DVT of the lower limbs, 268 (37.0%) pre-
sented with a DCVT and 457 (63.0%) with a MCVT (Fig,
Table I). Patients were a median age of 61 years (full range,
18-97), 42.2% were men, and 25.4% were inpatients.
Characteristics of isolated distal DVT at diagnosis.
Among the 268 DCVT, 40 (14.9%) affected the calf trifur-
cation, 115 (42.9%) the posterior tibial veins, and 113
(42.2%) the peroneal veins. Ten (3.7%) affected both legs.
Among the 457 patients with isolated MCVT, 250 (54.7%)
presented a soleal DVT and 207 (45.3%) a gastrocnemius
DVT. In 29 (6.3%), MCVT were bilateral. MCVT and
DCVT exhibited a similar diameter of clot under compres-
sion on US (6.4 vs 6.1 mm, respectively; P  .16 respec-
tively).
Clinical presentation at diagnosis. Localized pain
was significantly more frequent in case of MCVT (30.4% vs
22.4%, P  .02), whereas in case of DCVT, higher fre-
quency was found for swelling (62.7% vs 47.9%, P .001)
).
JOURNAL OF VASCULAR SURGERY
Volume 52, Number 4 Galanaud et al 935and a high pretest Wells probability score (ie,>2; (50.8% vs
41.2%, P  .01). There was no difference between MCVT
and DCVT in warmth (16.2% vs 17.2%, P  .7) and dull
pain (70.5% vs 67.9%, P .47). There was no difference in
time lag between the onset of symptoms and the realization
of the complete US examination between MCVT and
DCVT (5.8 vs 5.0 days, P  .09).
Risk factors for DVT at diagnosis. Risk factors are
reported in Table I. Of the isolated DCVT, 7.5% were
idiopathic, as were 11.2% of the isolated MCVT. Univariate
analysis identified no significant difference in the risk factors
profile between MCVT and DCVT. Multivariate analysis
only evidenced that recent surgery was significantly more
associated with DCVT (OR, 1.70; 95% CI, 1.06-2.75; P
.03). Compared to unilateral MCVT, bilateral MCVT were
significantly and independently more associated with active
cancer (OR, 4,6; 95% CI, 1.7-12.4) and age 75 years
(OR, 25.3; 95% CI, 3.1-207.9). The number of bilateral
DCVT was too small to perform a comparison of risk factor
profile with unilateral DCVT.
Charlson index. There was no difference in comor-
bidities: 69.1% of MCVT patients and 70.5% of DCVT
patients had no comorbidity (Charlson, 0), and 16% in
both groups had two or more comorbidities.
Three-month outcomes. Among the 222 DCVT and
Table I. Patient characteristics at baseline and risk factors
deep calf vein thrombosis (DCVT) by univariate and multi
Characteristics
Patients, No.
Age, median (IQR), y 6
Age class, No. (%)
50 years 8
51-75 years 13
75 years 5
Men, No. (%) 11
Inpatients, No. (%) 7
Anticoagulant treatment, No. (%) 6
Risk factors for venous thromboembolism
Transient risk factors, No. (%)
Bed confinement 4
Recent plaster immobilization of lower limb(s) 2
Recent travel 1
Recent surgery (45 days) 6
CHF or respiratory insufficiency
Acute infectious disease, n (%)
Pregnancy or postpartum 6 weeks
Chronic risk factors, No. (%)
Personal history of DVT or PE 8
Family history of DVT or PE 5
Active cancer 3
Varicose veins 6
Oral contraception 1
Hormone replacement therapy
Obesity (BMI 30 kg/m2) 3
BMI, Body mass index; CHF, congestive heart failure; CI, confidence interva
embolism.
aP  .10 in patients with deep calf DVT vs muscular calf DVT (no P  .05390 MCVT with follow-up data at 3 months, there was nodifference in death, VTE recurrence, and major bleeding
between MCVT and DCVT (Table II). Idiopathic MCVT
and DCVT 3-month outcomes did not differ from that of
MCVT and DCVT associated with a transient or a chronic
risk factor for VTE (data not shown). The 29 bilateral
MCVT patients exhibited a 17.4% risk of dying at 3 months
vs 3.0% for unilateral MCVT patients (P  .008). The
independent expert committee validated all declared
deaths, 69% of declared VTE recurrence, and 33% of de-
clared major bleedings.
Causes of death. The rate of death by PE, bleeding,
and cancer was the same between MCVT and DCVT
solated muscular calf vein thrombosis (MCVT) vs isolated
te analyses
T MCVT
DCVT vs MCVT
OR 95% [CI]
8 457 . . .
-97) 62 (18-97) . . .
.0) 137 (30.0) Ref
.5) 210 (46.0) 1.20 [0.78-1.87]
.5) 110 (24.1) 1.19 [0.69-2.04]
.9) 191 (41.8) 1.11 [0.78-1.58]
.1) 114 (24.9) 1.13 [0.70-1.84]
.1) 103 (22.5) 0.82 [0.51-1.31]
.9) 85 (18.6) 0.76 [0.46-1.24]
.4) 31 (6.8)a 1.86 [0.98-3.53]
7) 27 (5.9) 1.36 [0.67-2.73]
.8) 78 (17.1)a 1.70 [1.06-2.75]
0) 21 (4.6) 0.70 [0.28-1.75]
7) 6 (1.3) 0.82 [0.14-4.75]
5) 4 (0.9) 2.38 [0.48-11.74]
.3) 144 (31.5) 1.07 [0.73-1.57]
.5) 86 (18.8) 1.13 [0.74-1.75]
.9) 49 (10.7) 1.16 [0.68-1.96]
.9) 121 (26.5) 0.90 [0.60-1.36]
7) 26 (5.7) 1.13 [0.51-2.49]
4) 6 (1.3)a 2.82 [0.89-8.96]
.6) 59 (12.9) 0.91 [0.54-1.52]
T, deep vein thrombosis; IQR, interquartile; OR, odds ratio; PE, pulmonary
Table II. Clinical outcomes at 3 months in patients with
isolated muscular calf deep vein thrombosis (MCVT) vs
isolated deep calf vein thrombosis (DCVT) by univariate
and multivariate analyses
Outcome
DCVT
(n  222)
MCVT
(n  390) DCVT vs MCVT
No. (%) No. (%) OR (95% CI)
Death 9 (4.1) 15 (3.8) 0.98 (0.24-4.11)
Recurrent VTE 3 (1.4) 6 (1.5) 0.98 (0.24-4.11)
Major bleeding 1 (0.5) 0 (0) . . .
CI, Confidence interval; OR, odds ratio; VTE, venous thromboembolism.for i
varia
DCV
26
1 (18
3 (31
0 (48
5 (20
5 (42
0 (26
2 (23
0 (14
8 (10
8 (6.
1 (22
8 (3.
2 (0.
4 (1.
4 (31
5 (20
2 (11
4 (23
8 (6.
9 (3.
1 (11
l; DVpatients (Table III).
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was administered to 3.6% of patients in both groups.
DCVT patients were treated significantly longer, 86.5% of
DCVT and 76.7% of MCVT were treated during the entire
3-month follow-up (P  .0031, Table IV).
DISCUSSION
This study’s primary result is that MCVT and DCVT
exhibit the same risk factors profile and Charlson index,
suggesting that they affect the same patient population.
Furthermore, under anticoagulant treatment, their prog-
nosis was similar at 3 months.
In a previous analysis of the OPTIMEV study and in
the Registro Informatizado de la Enfermedad Tromboem-
bólica (RIETE) registry, we evidenced that according to
their proximal or distal level, isolated symptomatic DVT of
the lower limbs shared the same risk factors, but the weight
of these risk factors was different.15,16 Indeed, isolated
distal DVT was more strongly associated with transient risk
factors, whereas proximal DVT was more associated with
chronic states. This could suggest that the population
profile might vary according to the level of the symptomatic
isolated DVT. This may at least partly explain why if one
assumes that most DVTs originate in the muscle calf veins,
only a limited number will extend at a more proximal
level.25 Our results, however, demonstrate that these two
populations of isolated distal DVT are strictly comparable
in risk factors and comorbidities. In contrast to McDonald
et al,13 who evidenced that active cancer was associated
Table III. Causes of death at 3 months of patients with
isolated distal deep vein thrombosis
Cause
DCVT (n  222) MCVT (n  390)
No. (%) No. (%)
Total death 9 (4.1) 15 (3.8)
Pulmonary embolism 2 (0.9) 2 (0.5)
Bleeding 0 (0) 0 (0)
Cancer 4 (1.8) 7 (1.8)
Other 3 (1.4) 6 (1.5)
DCVT, Deep calf vein thrombosis; MCVT, muscular calf deep vein throm-
bosis.
Table IV. Anticoagulant treatment received, according
to the location of the distal deep vein thrombosis
Variable
DCVT MCVT
No. (%) No. (%)
No treatment 8 (3.6) 14 (3.6)
LMWH only 18 (8.4) 53 (14.1)
Prophylactic regimen 1 (5.6) 1 (1.9)
Full therapeutic dose 17 (94.4) 49 (92.5)
Unknown dose . . . 3 (5.7)
LMWH  VKA 191 (89.3) 312 (83.0)
Unknown anticoagulant 5 (2.3) 11 (2.9)
DCVT, Deep calf vein thrombosis; LMWH, low-molecular-weight heparin;
MCVT, muscular calf deep vein thrombosis; VKA, vitamin K antagonist.with a significant risk of extension of MCVT to DCVT, wecould not determine any clinical characteristics more asso-
ciated with DCVT and thus acting as a potential provider
for proximal extension of MCVT.13 Our short time lag of
5.3 days (equivalent between MCVT and DCVT) between
the onset of symptoms and the realization of the CUS
examination—and therefore the initiation of the anticoag-
ulant treatment—may explain this absence of difference.
This similar population profile and the fact that most
patients were treated with anticoagulant therapy probably
explain why the 3-month clinical outcomes did not signif-
icantly differ between MCVT and DCVT, whatever the
kind of outcome considered. The profile of causes of death
was also equivalent, with similar rates of deaths by cancer
(1.8% for both), PE (0.5% vs 0.9%, respectively), and bleed-
ing (0% for both). However, 3 months is probably too short
to evaluate difference in terms of mortality and VTE recur-
rence rates. Nevertheless, this time lag was sufficient to evi-
dence a more severe prognosis for bilateral MCVT, with a
3-month patient fatality rate of 17.4% (relative risk, 5.8; 95%
CI, 2.0-16.8), even greater than the 6.1% rate for unilateral
proximal DVT (relative risk, 2.9; 95% CI, 1.1-7.4).15 This
suggests that those DVT should probably at least be diag-
nosed to evidence a population at high risk, as previously
described for bilateral proximal and distal DVT.15,26
Finally, MCVT and DCVT differ in terms of clinical
presentation. Indeed, MCVTs that were more superficial
were more associated with local symptoms (local pain),
whereas DCVT were more associated with general symp-
toms, with swelling, and with positive pretest probability.
Our study presents a number of strengths and limitations.
Among the strengths, the large number of DVT included
(725 distal DVT) should be pointed out. The proportion of
isolated distal DVT (56.3% of all DVT),3,4,6,7,19 isolated
MCVT (49% of all distal DVT),3,5,7 and soleal DVT (54.7% of
MCVT)5,27 is consistent with that of previous studies. Our
DVT populations were homogeneous because we re-
stricted our analysis to isolated symptomatic MCVT and
DCVT, excluding asymptomatic DVT, joint MCVT and
DCVT, distal DVT with proximal extension, and PE.
Among the limitations of our study, we cannot exclude
that some distal DVT were misclassified. Indeed, Schwarz
et al28 demonstrated that the interobserver agreement de-
creases the further distal one goes. However, our CUS
examinations were all performed by well-trained vascular
medicine physicians according to a rigorous protocol and
all regularly attended Société Française de Médecine Vas-
culaire (SFMV) continuous medical education programs.
In OPTIMEV, the 3-month thromboembolic risk in
case of the first negative CUS examination was as low as
0.8% (15 of 1756), evidencing the safety of the procedure
to exclude DVT.17,18 Finally, as stated by Schellong et
al,2,19 after 200 supervised CUS examinations, such an
exploration is not more error prone than other vascular
ultrasound procedures. Furthermore, the protocol stipu-
lated that only clots with a diameter under compression on
US of 5-mm or more were considered as significant, which
reduces the risk of false-positive examination results and the
risk of misclassification. However, in 55 cases, clots with a
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distal DVT (31 DCVT, 24 MCVT) by the vascular medi-
cine physician who performed the US examination (proto-
col violation). Because their management and outcomes
were equivalent to that of clots 5 mm and they repre-
sented 10% of all distal DVT, we kept them in the
analysis. We do not have the information on the manage-
ment and outcomes of smaller clots because the diameter
under compression was reported in the case report form
only in the event of a positive US examination result.
The reliability of the outcome data may have been
impaired by the lack of medical visits, although every event
suspected by phone screening was confirmed by a medical
record. We may also have missed a significant difference in
terms of VTE recurrence or of PE between those DVT,
because most patients were receiving anticoagulant treat-
ment during the entire follow-up, DCVT being treated
slightly but significantly longer than MCVT. MCVT and
DCVT natural history are not assessable in this context.
Two recent observational studies reported higher rates of
VTE recurrence, but the context was different, with a
longer follow-up and either a high proportion of lost to
follow-up (50%) or a significantly higher proportion of
history of DVT among DVT patients.27,29
CONCLUSIONS
The present results showed that isolated symptomatic
MCVT and DCVT populations exhibit different clinical
symptoms at presentation but affect the same population,
with the same early outcome. In this context we can hy-
pothesize, that under anticoagulant treatment and in the
short term, isolated distal DVT constitute a homogeneous
entity. If bilateral MCVT prognosis was found to be severe,
probably justifying the detection of MCVT, this leaves
open the key question of up to which level of distality it is
necessary to treat lower limbs DVT with anticoagulant
drugs. The ongoing Contention alone versus Anticoagula-
tion for symptomatic Calf vein Thrombosis diagnosed by
UltraSonography (CACTUS) study (NCT00539058) may
therefore provide important elements of clarification thanks
to subgroups analyses according to the muscular or deep
calf vein location of the thrombus.
We are indebted to Carole Rolland for data manage-
ment; Catherine Blanie, Maryline Blanc, Marion Proust,
Sandrine Massicot, Ludovic Delhomme, Cathy Maillard,
and Caroline Bonnet for data monitoring and patient
follow-up, and Dominique Brisot, for his careful critical
revision of the manuscript.
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